Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403

Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Daisuke Minami, Toshi Murakami, Toshihide Yokoyama, Daijiro Harada, Shoichi Kuyama, Hirohisa Ichikawa, Koji Inoue, Daizo Kishino, Masaaki Inoue, Nagio Takigawa, Takuo Shibayama, Shingo Harita, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy for patients with EGFR-mutated non–small-cell lung cancer (NSCLC) have shown a significantly better objective response rate and progression-free survival than platinum doublet therapy. However, acquired resistance often occurs within 12 months. One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. The aim of the present study is to investigate the efficacy and safety of EGFR-TKI readministration with afatinib in patients with advanced NSCLC harboring activating EGFR mutations without T790M. The primary endpoint is progression-free survival. The secondary endpoints include the objective response rate, disease control rate, overall survival, toxicity, and quality of life. A total of 12 patients will be enrolled in this trial.

Original languageEnglish
Pages (from-to)241-244
Number of pages4
JournalClinical Lung Cancer
Volume18
Issue number2
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Lung Neoplasms
Mutation
Disease-Free Survival
Platinum
Survival Rate
Quality of Life
BIBW 2992
Safety
Therapeutics

Keywords

  • Epidermal growth factor receptor
  • Non–small-cell lung cancer
  • Readministration
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M : Okayama Lung Cancer Study Group Trial OLCSG 1403. / Oda, Naohiro; Ichihara, Eiki; Hotta, Katsuyuki; Ninomiya, Kiichiro; Ninomiya, Takashi; Kubo, Toshio; Minami, Daisuke; Murakami, Toshi; Yokoyama, Toshihide; Harada, Daijiro; Kuyama, Shoichi; Ichikawa, Hirohisa; Inoue, Koji; Kishino, Daizo; Inoue, Masaaki; Takigawa, Nagio; Shibayama, Takuo; Harita, Shingo; Tanimoto, Mitsune; Kiura, Katsuyuki.

In: Clinical Lung Cancer, Vol. 18, No. 2, 01.03.2017, p. 241-244.

Research output: Contribution to journalArticle

Oda, Naohiro ; Ichihara, Eiki ; Hotta, Katsuyuki ; Ninomiya, Kiichiro ; Ninomiya, Takashi ; Kubo, Toshio ; Minami, Daisuke ; Murakami, Toshi ; Yokoyama, Toshihide ; Harada, Daijiro ; Kuyama, Shoichi ; Ichikawa, Hirohisa ; Inoue, Koji ; Kishino, Daizo ; Inoue, Masaaki ; Takigawa, Nagio ; Shibayama, Takuo ; Harita, Shingo ; Tanimoto, Mitsune ; Kiura, Katsuyuki. / Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M : Okayama Lung Cancer Study Group Trial OLCSG 1403. In: Clinical Lung Cancer. 2017 ; Vol. 18, No. 2. pp. 241-244.
@article{bd26fbdc9e474fc193fdbe164bddc210,
title = "Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403",
abstract = "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy for patients with EGFR-mutated non–small-cell lung cancer (NSCLC) have shown a significantly better objective response rate and progression-free survival than platinum doublet therapy. However, acquired resistance often occurs within 12 months. One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. The aim of the present study is to investigate the efficacy and safety of EGFR-TKI readministration with afatinib in patients with advanced NSCLC harboring activating EGFR mutations without T790M. The primary endpoint is progression-free survival. The secondary endpoints include the objective response rate, disease control rate, overall survival, toxicity, and quality of life. A total of 12 patients will be enrolled in this trial.",
keywords = "Epidermal growth factor receptor, Non–small-cell lung cancer, Readministration, Tyrosine kinase inhibitor",
author = "Naohiro Oda and Eiki Ichihara and Katsuyuki Hotta and Kiichiro Ninomiya and Takashi Ninomiya and Toshio Kubo and Daisuke Minami and Toshi Murakami and Toshihide Yokoyama and Daijiro Harada and Shoichi Kuyama and Hirohisa Ichikawa and Koji Inoue and Daizo Kishino and Masaaki Inoue and Nagio Takigawa and Takuo Shibayama and Shingo Harita and Mitsune Tanimoto and Katsuyuki Kiura",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.cllc.2016.07.003",
language = "English",
volume = "18",
pages = "241--244",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M

T2 - Okayama Lung Cancer Study Group Trial OLCSG 1403

AU - Oda, Naohiro

AU - Ichihara, Eiki

AU - Hotta, Katsuyuki

AU - Ninomiya, Kiichiro

AU - Ninomiya, Takashi

AU - Kubo, Toshio

AU - Minami, Daisuke

AU - Murakami, Toshi

AU - Yokoyama, Toshihide

AU - Harada, Daijiro

AU - Kuyama, Shoichi

AU - Ichikawa, Hirohisa

AU - Inoue, Koji

AU - Kishino, Daizo

AU - Inoue, Masaaki

AU - Takigawa, Nagio

AU - Shibayama, Takuo

AU - Harita, Shingo

AU - Tanimoto, Mitsune

AU - Kiura, Katsuyuki

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy for patients with EGFR-mutated non–small-cell lung cancer (NSCLC) have shown a significantly better objective response rate and progression-free survival than platinum doublet therapy. However, acquired resistance often occurs within 12 months. One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. The aim of the present study is to investigate the efficacy and safety of EGFR-TKI readministration with afatinib in patients with advanced NSCLC harboring activating EGFR mutations without T790M. The primary endpoint is progression-free survival. The secondary endpoints include the objective response rate, disease control rate, overall survival, toxicity, and quality of life. A total of 12 patients will be enrolled in this trial.

AB - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy for patients with EGFR-mutated non–small-cell lung cancer (NSCLC) have shown a significantly better objective response rate and progression-free survival than platinum doublet therapy. However, acquired resistance often occurs within 12 months. One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. The aim of the present study is to investigate the efficacy and safety of EGFR-TKI readministration with afatinib in patients with advanced NSCLC harboring activating EGFR mutations without T790M. The primary endpoint is progression-free survival. The secondary endpoints include the objective response rate, disease control rate, overall survival, toxicity, and quality of life. A total of 12 patients will be enrolled in this trial.

KW - Epidermal growth factor receptor

KW - Non–small-cell lung cancer

KW - Readministration

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84995563222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995563222&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2016.07.003

DO - 10.1016/j.cllc.2016.07.003

M3 - Article

C2 - 27506489

AN - SCOPUS:84995563222

VL - 18

SP - 241

EP - 244

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -